Biomea Fusion, Clinical trial and BMF-219
US FDA lifts clinical hold on Biomea's diabetes trials
Biomea Fusion said on Thursday the U.S. Food and Drug Administration lifted a clinical hold on ongoing studies of its experimental drug for type 1 and 2 diabetes, sending its shares up 6.9%. The decision comes as a boon for the company as the regulator placed a hold on two trials of its lead drug,
Biomea Fusion: FDA Lifts Hold on Diabetes-Treatment Trials
Biomea Fusion said the Food and Drug Administration lifted its clinical hold on continuing clinical trials of the company's diabetes drug.
Balanced Outlook with a Hold Rating for Biomea Fusion Amidst Upcoming Milestones and Clinical Developments
Analyst Srikripa Devarakonda of Truist Financial maintained a Hold rating on Biomea Fusion (BMEA – Research Report), with a price target
FDA lifts hold on Bio­mea’s di­a­betes tri­als
The FDA lifted a clinical hold on two trials testing Biomea Fusion’s diabetes treatment. The news, announced Thursday, sent the company’s shares $BMEA up by about 4% to $9.11, inching closer to its June stock price of $11.
US FDA lifts clinical hold on Biomea's diabetes trials after safety review
The U.S. Food and Drug Administration lifted a clinical hold on Biomea Fusion's ongoing studies of its experimental drug for type 1 and type 2 diabetes, the drug developer said on Thursday. The regulator had placed a hold on two trials of its lead drug,
Biomea Fusion : FDA Lifts Clinical Hold On BMF-219 For Type 1 And Type 2 Diabetes Trials; Stock Up
Biomea Fusion Inc. (BMEA) announced that the U.S. Food and Drug Administration has lifted the clinical hold on the company's ongoing
Biomea Fusion Hold Rating: FDA Clearance and Increased Price Target Amid Cautious Optimism
Barclays analyst Peter Lawson has reiterated their neutral stance on BMEA stock, giving a Hold rating yesterday. Peter Lawson has given his ...
Approvals News | Today's Latest Stories | Reuters
Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...
devdiscourse12h
Current Updates: Major Developments in Health Sector
This summary highlights major health news, including Bavarian Nordic's UNICEF agreement for mpox vaccines, Pfizer's ...
Biomea Fusion, Inc. May Have Violated Securities Laws And The Schall Law Firm Urges Shareholder Participation In An Inquiry
NDAQ:BMEA) Biomea Fusion, Inc. May Have Violated Securities Laws And The Schall Law Firm Urges Shareholder Participation In An Inquiry ...
bovnews8d
Why Biomea Fusion Inc (BMEA) Stock is Currently 13.47% Above from Its 20-Day SMA?
Biomea Fusion Inc (BMEA) stock saw a modest uptick, ending the day at $8.26 which represents a slight increase of $0.28 or 3.51% from the prior close of $7.98. The stock opened at $8.03 and touched a ...
Medscape1d
Tirzepatide Leads to Long-Term Glucose Control
While several factors predict sustained glycemic control, predictors of sustained weight control with tirzepatide appear ...
news.stocktradersdaily12d
(BMEA) Investment Analysis
Check the time stamp on this data. Updated AI-Generated Signals for Biomea Fusion Inc. (BMEA) available here: BMEA.